Mutations: APP KM670/671NL (Swedish), APP V717F (Indiana)
Modification: APP: Transgenic
Disease Relevance: Alzheimer's Disease
Strain Name: B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
Genetic Background: C57BL/6 x C3HeJ; backcrossed to C57BL/6
Availability: The Jackson Lab; available through the JAX MMRRC Stock# 034846; Cryopreserved
This mouse enables regulated expression of mutant APP using a tet-off system. A tetracycline-responsive promoter drives the expression of an APP transgene bearing both the Swedish and Indiana mutations. When bred to transgenic mice expressing reverse tertracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA), the expression of the APP transgene can be turned off with the tetracycline analog, doxycycline, in bigenic animals.
Four lines of bigenic animals were reported together (Jankowsky et al., 2005). All four lines express APP protein at levels 10-30 fold higher than endogenous mouse APP and the transgene is nearly completely suppressed (>95 percent) following doxycycline treatment for as little as two weeks. Of the four lines, line 107 was the most well characterized and was found to have an intermediate level of transgene expression and to require an intermediate concentration of doxycycline for transgene suppression (see also line 102 and line 885).
When bred to animals producing tTA under the control of the CaMKIIα promoter, bigenic mice overproduce Aβ42 and amyloid deposition occurs as early as two months of age. Amyloid burden increases with age and by nine months the hippocampus and cortex have extensive amyloid pathology. Suppression of the APP transgene with doxycycline halts the progression of amyloid pathology. Mice also have progressive neuronal atrophy especially in the granule cell layer of the dentate gyrus (Jankowsky et al., 2005).
This model was previously available at The Jackson Lab as Stock# 007052.
Mouse APP695 with a humanized Aβ region and the Swedish (KM570/571NL) and Indiana (V617F) mutations downstream of a tetracycline-responsive promoter and mouse prion protein exons 1-2.
The CaMKIIα-tTA transgene inserted on chromosome 12, resulting in a 508 kb deletion that affects five mouse genes: Vipr2 (vasoactive intestinal peptide receptor 2), Wdr60 (WD repeat-containing protein 60), Esyt2 (extended synaptotagmin-like protein 2), Ncapg2 (non-SMC condensin II complex, subunit G2), and Ptprn2 (protein tyrosine phosphatase, receptor type, N polypeptide 2) (Goodwin et al., 2017). It is not known to what extent, if any, disruption of these mouse genes contributes to the development of the CAMKIIα-tTA X TetO-APPSweInd phenotype.
Research Models Citations
- Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005 Dec;2(12):e355. Epub 2005 Nov 15 PubMed.
- Goodwin LO, Splinter E, Davis TL, Urban R, He H, Braun RE, Chesler EJ, Kumar V, van Min M, Ndukum J, Philip VM, Reinholdt LG, Svenson K, White JK, Sasner M, Lutz C, Murray SA. Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis. bioRxiv preprint first posted online Dec. 18, 2017